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Abstract	
	While	the	mechanisms	and	quantitative	details	are	complex,	few	analysts	would	doubt	that	antibiotic	use	increases	the	prevalence	of	drug-resistant	bacterial	pathogens	among	all	bacteria	causing	disease	in	a	population.	The	causal	connection	between	antibiotic	use	and	the	total	incidence	of	severe	bacterial	infections,	possibly	mediated	by	antibiotic	resistance,	is	less	clearly	established.	The	increasing	burden	of	severe	bacterial	infections	and	their	sequelae,	particularly	sepsis,	in	the	United	States	and	other	countries,	calls	out	for	an	explanation.	In	this	Perspective	we	consider	the	evidence	bearing	on	the	hypothesis	that	prevalence	of	antibiotic	resistance	and	levels	of	antibiotic	use	are	important	contributors	to	the	rates	of	sepsis	hospitalizations	and	other	outcomes	with	bacterial	etiology.	In	the	process,	we	discuss	the	consequences	of	resistance	to/use	of	commonly	prescribed	antibiotics,	including	fluoroquinolones,	and	provide	a	comparison	of	the	epidemiology	of	antibiotic	use/resistance	and	severe	outcomes	associated	with	infections	with	bacterial	pathogens,	particularly	Escherichia	coli,	methicillin-resistant	Staphylococcus	aureus	(MRSA),	and	Clostridium	Difficile	in	the	UK	vs.	US.	
				Rates	of	hospitalization	with	septicemia	or	sepsis,	and	related	mortality,	as	well	as	the	associated	monetary	costs	have	been	increasing	during	the	past	decades	in	the	US	[1-3].	The	estimated	number	of	US	hospitalizations	with	septicemia	(ICD-9	codes	038.xx	present	on	the	discharge	diagnosis)	nearly	doubled	from	836,600	in	2000	to	1,665,500	in	2009	[1].	During	the	same	period,	the	estimated	number	of	in-hospital	deaths	for	hospitalizations	with	septicemia	increased	by	61%,	from	163,688	to	267,329	(Table	1	in	[1]).	The	CDC	estimates	that	about	250,000	Americans	die	from	sepsis	each	year,	with	one	in	three	patients	who	die	in	a	hospital	having	sepsis	[4].	These	mortality	counts	underestimate	the	number	of	deaths	resulting	from	hospitalizations	with	septicemia	in	the	US.	For	US	hospitalizations	with	
septicemia/sepsis	in	the	elderly,	the	90-day	case	fatality	rate	is	significantly	higher	than	the	in-hospital	mortality	rate	[5].	Therefore,	the	number	of	sepsis-related	deaths	in	the	US	would	be	substantially	larger	than	the	CDC	estimate	in	[4]	if	90-day	mortality	were	considered.	Also,	only	a	fraction	of	septicemia-related	deaths,	even	those	that	take	place	in	the	hospital,	have	septicemia	listed	on	the	death	certificate	([1]	vs.	[6]).	In	fact,	there	is	a	significant	discrepancy	between	hospital	discharge	diagnoses	and	the	lists	of	causes	of	death	on	death	certificates	in	the	US,	with	death	certificates	potentially	underestimating	infections	and	sepsis	as	proximal	causes	of	death	[7,8].		The	estimated	number	of	hospitalizations	with	septicemia	in	the	principal	discharge	diagnosis	increased	by	a	further	81%	between	2009-2014	[1,2].	Hospitalizations	with	septicemia	in	the	principal	diagnosis	alone	in	2013	cost	over	$23	billion	[3].	However,	rates	of	hospitalizations	meeting	certain	clinical	criteria	(defined	in	[9])	indicative	of	sepsis	remained	stable	during	the	same	period	[9].	Moreover,	the	proportion	of	hospitalizations	with	septicemia/sepsis	in	the	diagnosis	that	have	a	positive	blood	culture	has	declined	in	various	places	in	the	US	[10].	Change	in	diagnostic	practices	for	septicemia/sepsis	is	an	important	contributing	factor	to	the	increase	in	the	volume	of	hospitalizations	with	septicemia/sepsis	in	the	diagnosis,	especially	since	mid	2000s.		In	particular,	adoption	of	electronic	sepsis	screening	and	treatment	protocols	took	place	in	many	hospitals,	with	such	protocols	having	both	beneficial	and	adverse	effects	[11,12].	However,	changes	in	diagnostic	practices	do	not	provide	the	full	explanation	for	the	increase	in	the	rates	of	hospitalization	with	septicemia/sepsis	in	the	US,	particularly	prior	to	2009.	Indeed,	national	trends	in	US	hospitalization	rates	with	septicemia	and/or	sepsis	present	on	the	diagnosis	between	2003-2009	closely	resemble	the	trends	in	hospitalization	rates	with	both	an	infection	and	mechanical	ventilation	present	on	the	diagnosis	(Figure	1	in	[13]).	The	increase	in	the	rates	of	such	hospitalizations	associated	with	severe	infection	cannot	be	fully	explained	by	changes	in	diagnostic	practices.	Therefore,	factors	behind	the	rise	in	the	rates	of	hospitalization	with	septicemia/sepsis	in	the	diagnosis,	as	well	as	the	magnitude	of	those	rates	require	a	detailed	examination.			There	is	good	evidence	that	antimicrobial	resistance	increases	mortality	risk	for	sepsis,	importantly	by	reducing	the	probability	of	initially	appropriate	antibiotic	therapy	(IIAT)	[14,15].	However,	less	is	known	about	the	contribution	of	antibiotic	use	or	the	prevalence	of	antibiotic	resistance	to	rates	of	hospitalization	with	septicemia/sepsis.	Antibiotic	resistance	and	use	can	contribute	to	the	volume	of	hospitalizations	associated	with	bacterial	infections,	particularly	the	more	severe	ones,	through	several	mechanisms	[16].	Antibiotic	resistance	can	facilitate	the	progression	of	an	infection	into	a	more	severe	outcome	due	to	failure	of	initial	therapy	to	clear	the	infection.	This	mechanism	would	create	an	association	between	antibiotic	resistance	and	more	severe	types	of	infection.	For	example,	antibiotic	resistance	in	Enterobacteriaceae,	including	fluoroquinolone	resistance	in	
Escherichia	coli	was	found	to	be	associated	with	a	more	severe	presentation	in	urinary	tract	infections	[17,18].	In	England,	prevalence	of	amoxicillin-clavulanate	
(co-amoxiclav)	resistance	in	E.	coli-associated	bloodstream	infections	is	significantly	higher	than	in	E.	coli-associated	urinary	tract	infections	(Figures	2.1	vs.	2.7	in	[49]).	For	some	pathogens,	antibiotic	use	and	resistance	can	also	contribute	to	the	overall	increase	in	the	incidence	of	bacterial	infections	that	could	lead	to	severe	illness	episodes.	For	example,	receipt	of	fluoroquinolones	was	found	to	be	a	risk	factor	for	a	methicillin-resistant	Staphylococcus	aureus	(MRSA)	infection	[19-22],	while	receipt	of	different	antibiotics,	particularly	third	generation	cephalosporins	was	found	to	be	a	risk	factor	for	subsequent	colonization/infection	with	extended-spectrum	beta-lactamase-producing	Klebsiella	species	and	E.	coli	[23-25].	Furthemore,	reduction	in	ciprofloxacin	prescribing	in	a	London	hospital	was	associated	with	a	decline	in	the	incidence	of	MRSA	infections	[26].	We	also	note	that	several	biological	mechanisms	for	the	relation	between	fluoroquinolone	use	and	colonization	with	fluoroquinolone-resistant	staphylococci	were	proposed	[27,28].		In	a	recent	study	(Goldstein	et	al.	2018,	in	submission),	we	have	documented	associations	between	state-specific	prevalence	of	antibiotic	resistance	for	several	combinations	of	antibiotics/bacteria,	and	state-specific	rates	of	hospitalization	with	septicemia	in	US	adults.	Among	the	31	combinations	of	bacteria/antibiotics	studied	in	(Goldstein	et	al.	2018,	in	submission),	resistance	to	fluoroquinolones	in	E.	coli	had	the	strongest	association	with	septicemia	hospitalization	rates	in	adults	aged	50-64y,	65-74y,	75-84y,	and	85+y.	E.	coli	is	a	major	source	of	Gram-negative	septicemia	in	the	US	[1],	and	prevalence	of	fluoroquinolone	resistance	in	E.	coli	isolates	in	both	urinary	tract	and	bloodstream	infections	in	the	US	is	high	[29-32].		Changes	in	antibiotic	use,	both	in	the	inpatient	and	outpatient	settings	may	be	accompanied	by	corresponding	changes	in	rates	of	hospitalizations	associated	with	bacterial	infections,	including	sepsis.	At	the	population	level,		a	decline	in	fluoroquinolone	and	cephalosporin	use	in	England	was	accompanied	by	a	major	drop	in	the	rates	of	illness	and	death	associated	with	Clostridium	difficile	and	MRSA	infections	[33-36].	The	volume	of	fluoroquinolone	and	cephalosporin	prescribing	in	England	declined	between	2006-2013,	both	overall	and	in	the	inpatient	setting	(about	50%	reduction)	[33].	During	the	same	period,	incidence	of	C.	difficile	infections	and	MRSA	infections	and	bacteremia	in	England,	as	well	as	the	rates	of	associated	deaths	dropped	by	over	80%	[33-36].	Additionally,	the	proportion	of	C.	
difficile	infections	resistant	to	fluoroquinolones	declined	drastically	(e.g.	a	reduction	from	67%	in	2006	to	3%	in	2013	in	Oxfordshire,	[33]).		Rates	of	both	community-	and	hospital-associated	MRSA	bacteremia	in	England	also	showed	pronounced	declines	after	2006	(Figures	1	and	3	in	[35]).			The	US	had	more	concerning	trends	in	both	C.	difficile	infection	rates	and	MRSA	infection	rates	during	the	period	between	2006-2012	than	the	UK.	In	contrast	to	sharp	declines	in	the	UK,	C.	difficile	infections	in	the	US	continued	to	increase	[37].	While	the	rates	of	invasive	MRSA	infection	in	the	US	declined	between	2005-2011	[38],	the	drop	in	the	rates	of	MRSA	bacteremia	in	England	during	the	same	period	was	sharper,	particularly	for	community-associated	bacteremia	(compare	Figures	1	and	3	in	[35]	with	[38]).	One	factor	in	these	contrasting	patterns	may	be	contrasting	
patterns	of	fluoroquinolone	use.	In	the	US,	fluoroquinolone	use	in	adults	more	than	doubled	between	1995-2002	[39],	then	declined	in	the	hospital	setting	[40].	At	the	same	time,	fluoroquinolone	outpatient	prescription	rates	to	adults	were	stable	between	2000-2010	[41],	and	stable	in	older	adults	between	2011-2014	[42].	The	discrepancy	in	the	trends	in	outpatient	fluoroquinolone	prescribing	in	the	US	vs.	UK	may	partly	explain	why	the	rates	of	community-associated	invasive	MRSA	infections	in	the	US	remained	flat	between	2005-2011	[38],	while	rates	of	community-acquired	MRSA	bacteremia	in	the	UK	dropped	by	more	than	half	after	2006	(Figures	1	and	3	in	[35]).		We	also	note	the	high	prevalence	of	fluoroquinolone	(levofloxacin)	non-susceptibility	in	community-associated	MRSA	isolates	in	the	US	in	recent	years	[43].		A	recent	US	study	reported	a	17.5%	decrease	in	the	incidence	rates	of	long-term-care	onset	C.	difficile	infection	in	10	US	sites	between	2011-2015,	concomitant	with	the	ongoing	decrease	in	inpatient	fluoroquinolone	use	[44].	This	is	an	encouraging	reversal	of	the	earlier	trends	[37],	supporting	the	value	of	further	reductions	in	fluoroquinolone	prescribing.		In	recent	years,	FDA	has	issued	recommendations	against	fluoroquinolone	use	for	certain	conditions	(e.g.	uncomplicated	urinary	tract	infection)	due	to	potential	adverse	effects	[45].	It	remains	to	be	seen	what	the	effect	of	those	recommendations	will	be	on	fluoroquinolone	prescribing	in	the	US,	particularly	in	the	outpatient	setting,	and	the	rates	of	severe	outcomes	to	which	fluoroquinolone	use	and	resistance	contributes.		Reduction	in	fluoroquinolone	use	in	England	was	not	associated	with	a	reduction	in	the	rates	of	severe	outcomes	stemming	from	all	bacterial	pathogens	for	which	fluoroquinolone	resistance	prevalence	was	previously	high.	Levels	of	E.	coli	and	
Klebsiella-associated	bacteremia	were	continuing	to	rise	in	England	after	2006	[46,47].	Amoxicillin-clavulanate	(co-amoxiclav)	is	used	as	empiric	treatment	for	many	infection	syndromes	in	the	UK,	particularly	in	the	inpatient	setting	[48],	and	its	use	in	the	England	increased	significantly	after	2006	[49].	Moreover,	incidence	of	bacteremia	with	E.	coli	strains	resistant	to	amoxicillin-clavulanate	began	to	increase	rapidly	after	2006	([47],	Figure	4),	and	this	rise	was	faster	than	the	rise	in	incidence	of	bacteremia	with	susceptible	strains	[47].	By	2014,	over	40%	of	E.	coli-associated	bloodstream	infections	in	England	were	amoxicillin-clavulanate-resistant	(Figure	2.1	in	[50]).	This	suggests	that	use	of	and	resistance	to	different	antibiotics	may	help	sustain	the	growth	in	the	rates	of	E.	coli-associated	sepsis,	and	that	patterns	in	resistance	to	various	antibiotics	in	E.	coli	should	be	accounted	for	when	antibiotic	replacement	is	being	considered.	We	note	that	amoxicillin-clavulanate	use	in	England	began	to	decrease	after	2012,	and	trends	in	amoxicillin-clavulanate	resistance	among	E.	coli-associated	urinary	tract	infections	(UTIs)	began	to	change	as	well	([50],	Figures	2.1,	3.4).	In	the	US,	E.	coli	isolates	from	individuals	hospitalized	for	urinary	tract	infections	(UTIs)	and	bloodstream	infections	have	high	levels	of	amoxicillin	and	multidrug	resistance	[31,32],	while	most	UTI	E.	coli	samples	resistant	to	third-generation	cephalosporins	in	hospitalized	patients	in	[30]	were	also	resistant	to	fluoroquinolones.	While	the	results	in	(Goldstein	et	al.	2018,	in	submission)	support	the	contribution	of	fluoroquinolone	resistance	prevalence	to	
the	rates	of	E.	coli-associated	septicemia,	options	for	reducing	the	incidence	of	E.	
coli-associated	sepsis	in	the	US	through	replacement	of	fluoroquinolones	by	other	antibiotics	may	be	limited.	For	urinatry	tract	infections,	some	of	the	options	may	potentially	be	provided	by	antibiotics	like	nitrofurantoin	and	fosfomycin	that	are	largely	reserved	for	UTIs	and	may	be	less	likely	to	generate	resistance	compared	to	antibiotics	that	are	prescribed	more	widely	for	a	variety	of	conditions.	Data	from	Veterans	Affairs	hospitals	in	the	US	suggest	low	prevalence	of	non-susceptibility	to	nitrofurantoin	in	E.	coli-associated	UTI	hospitalizations	[31].	Data	from	the	English		Surveillance	Programme		for		Antimicrobial		Utilisation	and		Resistance	(ESPAUR)	suggest	low	prevalence	of	non-susceptibility	to	nitrofurantoin	and	fosfomycin	in	E.	
coli-associated	UTIs,	both	for	the	community	and	acute	hospital	isolates	(Figure	2.7	in	[50]).	Data	on	resistance	patterns	to	different	antibiotics	for	different	pathogens	that	cause	various	syndromes	(including	UTI-related	syndromes)	are	needed	to	inform	the	corresponding	treatment	guidelines.		The	results	in	(Goldstein	et	al.	2018,	in	submission)	suggest	that	prevalence	of	resistance	to	commonly	prescribed	antibiotics	contributes	to	the	rates	of	hospitalization	with	septicemia/sepsis	in	the	US.	Those	findings	support	the	need	for	enhancing	antibiotic	stewardship,	including	for	fluoroquinolone	use,	both	in	the	inpatient	and	outpatient	settings	[51],	and	for	preventing	acquisition	of	antibiotic-resistant	bacteria	(particularly	E.	coli	in	the	elderly,	e.g.	[52,53]).	The	findings	in	(Goldstein	et	al.	2018,	in	submission)	about	the	association	of	fluoroquinolone	resistance	in	E.	coli	with	the	rates	of	hospitalization	with	septicemia	complement	the	evidence	from	the	UK	about	the	parallel	declines	of	fluoroquinolone	resistance/use	and	the	rates	of	severe	outcomes	associated	with	bacterial	infections,	including	C.	difficile	infections	[33-35]	and	MRSA	infections	and	bacteremia	[34-36,26].	All	this	evidence	points	to	the	potential	benefit	of	reducing	fluoroquinolone	use	in	the	US,	both	in	the	outpatient	and	the	inpatient	settings.	A	recent	study	found	that	about	25%	of	outpatient	fluoroquinolone	prescriptions	to	US	adults	in	2014	were	for	conditions	that	did	not	require	antibiotics,	or	where	fluoroquinolones	are	not	recommended	first-line	therapy	[54].	These	considerations	might	reflect	the	tendency	to	use	commonly	prescribed	antibiotics	for	a	variety	of	conditions,	including	those	for	which	more	narrow-spectrum	antibiotics	are	available	and	recommended.	For	E.	coli-associated	urinary	tract	infections,	data	from	both	the	US	and	the	UK	suggest	that	prevelance	of	resistance	to	some	of	the	antibiotics	that	are	mostly	recommended	for	UTI	treatment,	such	as	nitrofurantoin	and	fosfomycin	is	significantly	lower	than	prevalence	of	resistance	to	the	more	widely	prescribed	antibiotics,	including	fluoroquinolones,	ampicillin,	amoxicillin,	amoxicillin-clavulanate,	and	trimethoprim/sulfamethoxazole	[31,50].	The	UK	experience	in	the	reduction	of	fluoroquinolone	and	cephalosporin	use	also	suggests	that	for	some	pathogens,	particularly	E.	coli,	resistance	to	some	of	the	replacing	antimicrobials	(e.g.	amoxicillin-clavulanate)	may	contribute	to	the	rates	of	associated	bacteremia	hospitalizations	[47].	Taken	together,	these	considerations	suggest	that	treatment	guidelines	for	each	particular	syndrome	should	account	for	patterns	of	resistance	to	different	antibiotics	for	various	pathogens	that	are	causative	agents	for	the	given	syndrome	[36,47].	The	study	of	patterns	of	antibiotic	
resistance	requires	surveillance	data	on	the	prevalence	of	disease	and	resistance	associated	with	different	pathogens	[36]	akin	to	the	one	described	in	[34-36,46-48,50].	We	note	that	such	surveillance	data	are	less	readily	available	in	the	US,	particularly	for	sepsis	and	bacteremia	hospitalizations.	Additionally,	evidence	on	the	causal	effect	between	patterns	in	antibiotic	resistance	and	use	and	the	incidence	of	hospitalizations	associated	with	bacterial	infections	is	limited.	Further	studies	in	that	regard	examining	antibiotic	receipt	prior	to	bacteremia/sepsis	hospitalization	and	diagnosis	(e.g.	during	treatment	of	UTIs,	gastrointestinal	infections	and	other	syndromes)	should	help	inform	public	health	policies.	Finally,	the	high	burden	of	severe	outcomes	stemming	from	bacterial	infections	that	is	associated	with	antibiotic	resistance	and	use,	and	the	limited	options	for	antibiotic	replacement	support	the	need	for	a	robust	supply	of	new	antibiotics	for	common	prescription.	This	need	may	not	be	fulfilled	through	the	current	system	of	antibiotic	development/production,	and	additional	incentives	for	antibacterial	research	and	development	are	worth	considering	[55].			
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